Phospatidylinositol 3-kinase expression in human breast cancer.
Phospatidylinositol 3-kinase (PI 3-kinase) expression was analysed by Western blotting with monoclonal antibodies to the p85 subunit in a series of tumour and adjacent mammary gland samples collected at surgery from 33 breast cancer patients. Seventy-nine percent of the investigated pairs of the samples were characterised by an increased level of PI 3-kinase in the tumour in comparison with the adjacent mammary gland. PI 3-kinase activation was not associated with tumour steroid receptor status, histologic grade and other clinico-morphological characteristics. Furthermore, immunoblotting of epidermal growth factor receptor (EGFR) in the tumours with increased PI 3-kinase and corresponding adjacent tissues revealed no association between EGFR and PI 3-kinase activation. Thus, increased PI 3-kinase expression appears to be a widespread feature of breast cancer not associated with the main biological markers of its prognosis and hormone sensitivity.
Gershtein
E S
ES
Laboratory of Clinical Biochemistry, Institute of Clinical Oncology, Cancer Research Centre, Moscow, Russia. es-gershtein@mtu-net.ru
Shatskaya
V A
VA
Ermilova
V D
VD
Kushlinsky
N E
NE
Krasil'nikov
M A
MA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000201:enzymology*; D004789:Enzyme Activation; D005260:Female; D006801:Humans; D008875:Middle Aged; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*
D014408:Biomarkers, Tumor; D019869:Phosphatidylinositol 3-Kinases